3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Hepatitis, Chronic
1
Hepatitis C
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Anal Canal Carcinoma
1
Interventions
pembrolizumab
36
Magnetic Resonance Spectroscopy
23
Gemcitabine
19
Specimen Handling
15
Nivolumab
12
Carboplatin
12
Surveys and Questionnaires
11
Paclitaxel
11
Cetuximab
11
Early Intervention, Educational
10
Bevacizumab
10
Standard of Care
9
Cyclophosphamide
9
Cisplatin
9
Radiosurgery
8
Methods
8
Fluorouracil
8
Docetaxel
8
Blood Specimen Collection
8
Psychiatric Rehabilitation
7
Pemetrexed
7
sargramostim
6
aldesleukin
6
Taxes
6
Injections
6
Fluorodeoxyglucose F18
6
Educational Status
6
Drug Therapy
6
Biopsy
6
Albumin-Bound Paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
rocakinogene sifuplasmid
×
Gastrointestinal
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled